The abstract is read at the publisher; the summary is JClub's.
Lean metabolic dysfunction-associated steatotic liver disease (MASLD) in 18,326 biopsy-confirmed adults shows milder histology but similar mortality and clinical event rates versus overweight/obese MASLD.
- Why it matters: Lean MASLD is increasingly recognized despite normal weight, yet its histologic profile and prognostic implications—and how well noninvasive fibrosis tests work—are unclear.
- What they did: In a multinational retrospective cohort from 41 countries, investigators compared lean versus overweight/obese MASLD using BMI and waist circumference, assessed fibrosis on biopsy, and evaluated FIB-4 and transient elastography liver stiffness measurement (LSM) for advanced fibrosis (F3-F4).
- The result: Lean status had lower type 2 diabetes (38.2% vs 48.3%) and advanced fibrosis (29.3% vs 37.2%), but was not independently linked to all-cause mortality (aHR, 0.90) or clinical events (aHR, 0.94); LSM predicted F3-F4 better in lean MASLD (AUC 0.87 vs 0.83).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.